Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights that prolonged voriconazole use is linked to an increased risk of aggressive cutaneous malignancies like squamous cell carcinoma, necessitating careful monitoring of drug levels to manage adverse effects.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

This article discusses various hair and nail abnormalities linked to paraneoplastic conditions and cancer treatments, emphasizing their potential role in diagnosing and managing internal malignancies and reports no new clinical findings.

This article discusses safety, management, and adverse effects of chemotherapy in gynecological malignancies without reporting new clinical data, and emphasizes the importance of thorough patient and drug selection.

This study discovered that minoxidil affects hematopoiesis by downregulating wnt4, leading to suppression of hematopoietic stem and progenitor cells and alleviating MDS-like symptoms in zebrafish and mice, with hematologic safety achieved at optimized doses.

This study presented cases where potentially significant germline variants were unexpectedly found during genomic profiling for myeloid malignancies, discussing the challenges in genetic counseling and management, especially when variants don't match the patient's condition.

This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.

This review discusses the hedgehog signaling pathway's role in cutaneous tumors and hematological disorders, highlighting its potential as a therapeutic target, but reports no new clinical findings.

In this case report and literature review, researchers observed that black hairy tongue syndrome can be improved by dietary restrictions and local care, identifying factors like antibiotics, malignancies, and certain medications as common triggers, with resolution achieved by eliminating these factors when possible.

In this narrative case report, the authors discuss a patient recently diagnosed with an early-stage hematologic malignancy, highlighting her skepticism toward conventional medicine and preference for natural remedies over pharmaceutical treatments.

This report details the first two cancer patients with COVID-19 and co-infection cases at the Instituto Nacional de Cancerología, ESE, and presents their clinical symptoms and complications.

This case report describes a 21-year-old man diagnosed with systemic lupus erythematosus, highlighting the condition's potential to mimic hematological malignancy and the effectiveness of prednisolone in rapid symptom improvement.

This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

This study found that long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m² per week with acceptable toxicity, and suggests further evaluation with 40 mg/m² for phase II studies.

This article presents a case of primary adrenal localization of non-Hodgkin's lymphoma in a 70-year-old woman, detailing her diagnosis and treatment, with no signs of recurrent disease after polychemotherapy and radiotherapy.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

Patients with GATA2 deficiency show early skin symptoms that help diagnose the condition.

This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.

This review describes current medical and surgical treatments for transgender men, highlighting the effectiveness and general tolerability of hormone treatment, and suggesting that surgical benefits often surpass associated risks, although it reports no new clinical findings.

In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.

This paper reviews seven major systemic causes of hair loss and provides a clinical evaluation framework but reports no new experimental results.

This study reported that new drugs, despite lower specificity compared to certain immunobiological therapies, are effective across various challenging dermatological diseases, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo.

This case report details a 31-year-old woman with a subcutaneous nodule on her hand characterized by necrosis and lymphocytic infiltrate.

This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

The study found that patients over 70 with advanced ovarian cancer may have better overall and progression-free survival with weekly paclitaxel-carboplatin chemotherapy compared to a three-weekly regimen, despite increased blood-related toxicities.